Annual Cancer Symposium - 2010 Scientific Program - Friday Sessions
Order Session DVDs HERE while supplies last.
Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters
Meet the Professor Breakfasts
6:15 – 7:15 am
Friday Registration Required • Fee: $45 • Limit: 30 per breakfast
B1 Pancreatic Cancer: My Approach
(Renaissance Hotel – Landmark 3)
Murray F. Brennan, MD Disclosure: None
B2 Evidence-Based Continuous Quality Improvement in Breast Cancer Practice: The State-of-the-Art and Science 2010
(Renaissance Hotel – Landmark 2)
Stephen B. Edge, MD Disclosure: None
B3 My Surgical Oncology Career: Private Practice or Academia? (Renaissance Hotel – Landmark 1)
Peter D. Beitsch, MD* Raphael E. Pollock, MD, PhD** *Disclosure: Speaker, Honorarium: SenoRx, Hologic, Xoft, Angendia, Genomic Health **Disclosure: None
B4 Surgical Management of the Very Difficult Pelvis (Renaissance Hotel – Landmark 5)
Philip B. Paty, MD Disclosure: None
B5 Utilization of the SEER and SEER-Medicare Databases for Oncology Research
(Renaissance Hotel – Landmark 6)
Janice N. Cormier, MD, MPH* Sandra L. Wong, MD, MS** *Disclosure: Speaker: Novartis Pharmaceutical **Disclosure: None
B6 Gastric and GE Junction Cancer: Principles of Surgical Management
(Renaissance Hotel – Landmark 7)
Daniel G. Coit, MD Disclosure: None
B7 Surgical Management of Hepatocellular Carcinoma (Renaissance Hotel – Majestic C)
David A. Geller, MD Disclosure: Consultant: Covidien, Applied Medical and Aloka
…continued on next page
B8 Patient-Reported Outcomes Research: How to Do It and How to Use It
(Renaissance Hotel – Majestic B)
Thomas Anthony, MD*
Nancy N. Baxter MD, PhD**
*Disclosure: Speaker: Merck Pharmaceutical
**Disclosure: None
B9 Basic Statistics for the Surgical Oncologist
(Renaissance Hotel – Majestic A)
Ulrich Guller, MD, MHS
Disclosure: None
Objectives: At the conclusion of this session, participants should be able to: (B1) describe the problems that surround the management of pancreatic cancer and discuss the evolution of management of pancreatic cancer over the last 30 years; (B2) define the need for practice based quality measurement; identify measures for practice based measurement and identify mechanisms for use of practice data in managed care contracting and quality improvement; (B3) discuss the pleasures and challenges of an academic surgical oncology career; (B4) recognize the wide variety of tumors that can arise in the pelvis; discuss the roles of diagnostic various modalities and examine both curative and palliative treatment strategies; (B5) provide an overview of SEER and SEERMedicare Databases for the use in oncology research; (B6) identify various options for surgical approach to adenocarcinoma of the GE junction and review evidence in support of each approach; (B7) define the current management of HCC and review minimally invasive hepatic resection for HCC; (B8) explain how to perform and use patient reported outcomes to facilitate better clinical practice; and (B9) discuss relevant and frequently encountered statistical topics (e.g., pvalue, hypothesis testing, absolute versus relative risk reduction, number needed to treat, confounding, and multivariable analysis).
Opening Announcements
7:30 – 7:45 am Friday Room 221-228 • America’s Center Fabrizio Michelassi, MD, President
James C. Cusack, Jr., MD, Scientific Program Chair David C. Linehan, MD, Local Arrangements Chair
Plenary Session I
7:45 – 8:45 am Friday
Room 221-228 • America’s Center
Moderator: Mitchell C. Posner, MD
Disclosure: None
7:45 am A Novel Targeted Biotherapeutic for Treatment of Pancreatic Cancer (1)
X. Qi,1* Z. Chu,1 M.B. Palascak,2 R.S. Franco,2
K.F. Stringer,1 S.A. Ahmad.2 1. Human Genetics, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH; 2. University of Cincinnati College of Medicine, Cincinnati, OH.
Disclosure: Advisory Board: Bexion Pharmaceuticals
8:00 am Trends in Centralization of Cancer Surgery (2)
K.B. Stitzenberg,1* N.J. Meropol.2 1. Surgery, UNCCH, Chapel Hill, NC; 2. Case Western Reserve University, Cleveland, OH.
Disclosure: None
8:15 am Invasive IPMN and MCN: Same Organ, Different Outcomes? (3)
H. Kargozaran,* V. Vu, P. Ray, S. Bagaria, X. Ye,
G. Singh. Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA.
Disclosure: None
8:30 am Extremity High Grade Soft Tissue Sarcoma (STS): Outcomes in Patients with Primarily Negative vs. Positive Converted to Negative Microscopic Margins Following Re-Excision (4)
G.J. Lahat,* D. Tuvin, K. Torres, B. Feig,
J.N. Cormier, K.K. Hunt, P.W. Pisters, D. Lev,
R.E. Pollock. MDACC, Houston, TX. Disclosure: None
Objectives: Upon completion of this session, participants should be able to: (1) identify a specific biotarget on human pancreatic cancer for a novel anticancer therapy; (2) discuss the impact of the volumeoutcomes literature on where cancer surgery is performed and discuss the potential implications of increasing centralization of cancer procedures; (3) recognize differences in the natural history of invasive pancreatic MCN and IPMN after resection; and (4) discuss the importance of positive microscopic margins as a prognosticator in extremity high grade sarcoma.
* designated presenter
8:45 – 9:30 am
SSO Presidential Address
Certification in Surgical Oncology
Fabrizio Michelassi, MD
Lewis Atterbury Stimson Professor Chairman, Department of Surgery Weill Cornell Medical College Surgeon¬in-Chief New York¬Presbyterian Hospital at Weill Cornell New York, NY
Disclosure: None
Objectives: Upon completion of this session, participants should be informed about the process of obtaining a certificate of subspecialty in Advanced Surgical Oncology.
9:30 – 10:00 am Refreshment Break in Exhibit Hall
Cast your vote for the Best Science and Clinical Posters. Ballots must be submitted by 1:00 pm Saturday.
Plenary Session II
10:00 – 10:45 am Friday Room 221-228 • America’s Center
Moderator: James S. Economou, MD
Disclosure: None
10:00 am Understanding Surgical Decision-Making in Early Hepatocellular Carcinoma (5)
H. Nathan,1* J.F. Bridges,2 R.D. Schulick,1 A.M. Cameron,1 K. Hirose,1 B.H. Edil,1 C.L. Wolfgang,1
D.L. Segev,1 M.A. Choti,1 T.M. Pawlik.1 1. Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD; 2. The Johns Hopkins University School of Public Health, Baltimore, MD.
Disclosure: None
10:15 am Update on DCIS Outcomes from the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Clinical Trial Registry (6)
J.S. Jeruss,1* H.M. Kuerer,2 P.D. Beitsch,3 F. Vicini,4
M. Keisch.5 1. Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL; 2. MD Anderson Cancer Center, Houston, TX; 3. Dallas Breast Center, Dallas, TX; 4. William Beaumont Hospital, Royal Oak, MI; 5. Miami Brachytherapy Center, Miami, FL.
Disclosure: None
10:30 am Mitotic Rate Predicts Sentinel Lymph Node Involvement in Melanoma: Impact of the 7th Edition AJCC Melanoma Staging System (7)
A.S. Caudle,* M.I. Ross, V.G. Prieto, C.L. Warneke,
J.E. Lee, M.M. Johnson, J.M. Gardner, R.E. Royal,
J.N. Cormier, A. Lucci, J.E. Gershenwald. MD Anderson Cancer Center, Houston, TX.
Disclosure: None
Objectives: Upon completion of this session, participants should be able to: (5) identify key factors that determine surgeons' choices of therapy for early hepatocellular carcinoma; (6) discuss the updated results of the ASBS accelerated partial breast irradiation registry trial for the treatment of DCIS; and (7) discuss the correlation between mitotic rate and sentinel lymph node positivity in cutaneous melanoma.
* designated presenter
10:45 – 11:00 am
Annual Heritage Presentation
Honoring Murray F. Brennan, MD SSO President 1995 – 1996
Presented by:
Timothy J. Eberlein, MD
Bixby Professor and Chairman Department of Surgery Director, Alvin J. Siteman Cancer Center Washington University School of Medicine St. Louis, MO
Supported by an educational grant from the American College of Surgeons Commission on Cancer
11:15 am – Noon
American Cancer Society/SSO Basic Science Lecture
The Cancer Epigenome: Origins and Translational Implications
Stephen Baylin, MD
Deputy Director, Professor of Oncology and Medicine Chief of the Cancer Biology Division and Director for Research The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD
Disclosure: Stocks, Consultant, Advisory Board, Research Grant: Oncomethylome Sciences Consultant, Research Grant: BioNumerik Pharmaceuticals, Inc., Constellation Pharmaceuticals Consultant, Advisory Board, Speaker, Honorarium: Progen Pharmaceuticals Consultant, Speaker, Honorarium: Cellgate, Inc., Syndax
Objectives: Upon completion of this session, participants should be able to: discuss the terms Epigenetics and some of the steps involved in the process and the concept, broadly, of a Cancer Epigenome.
Supported by an educational grant from the American Cancer Society
Noon – 1:00 pm Complimentary Lunch and Poster Viewing in Exhibit Hall
Parallel Session…Parallel Session…Parallel Session…
Gastrointestinal Cancer
1:00 – 3:00 pm Friday Room 221-228 • America’s Center
Moderators: Clifford S. Cho, MD* and Bridget N. Fahy, MD**
*Disclosure: None **Disclosure: Research Grant: Golfers Against Cancer
1:00 pm A Prospective Comparison of Cytoreductive Surgery Plus Heated Intraperitoneal Chemotherapy and Early Postoperative Chemotherapy vs. Heated Intraperitoneal Chemotherapy Alone in the Treatment of Peritoneal Carcinomatosis (8)
W.P. Francis,1* L.A. Mack,3 W.J. Temple,3
T. Hamilton,2 M.A. Frankson.4 1. Surgery, Princess Margaret Hospital, Nassau, New Providence, Bahamas; 2. University of Calgary, Calgary, AB, Canada; 3. Tom Baker Cancer Centre, Calgary, AB, Canada; 4. University of the West Indies, Nassau, New Providence, Bahamas
Disclosure: None
1:15 pm Evolution of Laparoscopic Liver Resection in 300 Patients (9)
• Buell,1* G. Brock,1 M. Marvin,1 M. Thomas,1
• Rudich,2 T. Doty,2 K. Bilinski,1 K. Ravindra,1
• Barve,1 G. Neff,1 L. Marsano,1 A. Barve,1
C. McClain,1 K. McMasters.1 1. Surgery, University of Louisville, Louisville, KY; 2. University of Cincinnati, Cincinnati, OH.
Disclosure: None
1:30 pm Multicenter Phase II Clinical Trial of Yttrium-90 Resin Microspheres Alone in Unresectable, Chemotherapy Refractory Colorectal Liver Metastases (10)
M. Cosimelli,1* R. Mancini,1 F. Izzo,2 F. Fiore,2
R. Golfieri,3 E. Giampalma,3 M.G. Diodoro,1
I. Sperduti,1 E. Melucci,1 M. Mottolese.1 1. Istituto Regina Elena, Rome, Italy; 2. G. Pascale Cancer Institute, Naples, Italy; 3. Malpighi Hospital, Bologna, Italy.
Disclosure: None
* designated presenter
1:45 pm Cyst Fluid Mucin Levels Predict Dysplasia in Intraductal Papillary Mucinous Neoplasms of the Pancreas (IPMN) (11)
• Maker,* N. Katabi, M. Gonen, R. DeMatteo,
• D'Angelica, Y. Fong, W. Jarnagin, M. Brennan,
P. Allen. Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None
2:00 pm Survival and Health-Related Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Disseminated Peritoneal Cancer of Colonic Origin (12)
A.R. Hill,* R.P. McQuellon, G.B. Russell, P. Shen,
J.H. Stewart, E.A. Levine. Wake Forest University Baptist Medical Center, WinstonSalem, NC.
Disclosure: None
2:15 pm The Basic Helix-Loop-Helix Transcription Factor ASCL1 Mediates Oncogenic Transformation in Gastrointestinal Neuroendocrine Tumor Cells (13)
Y. Wang,* D.B. Donner, E.K. Bergsland,
R.S. Warren, E.K. Nakakura. University of California San Francisco, San Francisco, CA.
Disclosure: None
2:30 pm Adjuvant Chemotherapy and Recurrence in Pathologically Node-negative Rectal Cancer After Neoadjuvant Chemoradiation and Total Mesorectal Excision (14)
A. Govindarajan,* M.R. Weiser, P.B. Paty,
L.K. Temple, J.G. Guillem, W.D. Wong, G.M. Nash.
Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None
2:45 pm Impact of Positive Peritoneal Cytology on Outcome in 291 Patients with Gastric Cancer (15)
J.J. Mezhir,* D.C. Coit, L.M. Jacks, M.A. Shah,
M.F. Brennan, V.E. Strong. Memorial-Sloan Kettering Cancer Center, New York, NY.
Disclosure: None
* designated presenter
Objectives: Upon completion of this session, participants should be able to: (8) discuss different methods of treatment for peritoneal carcinomatosis and compare and contrast the various methods of treatment with respect to length of stay and complications and understand its implication for clinical practice;
(9) discuss the role of minimally invasive techniques in liver resection in modern practice; (10) discuss the efficacy and safety of radioembolization for the management of unresectable colorectal liver metastases and summarize the advantages, disadvantages, and limitations of this technique in clinical practice;
(11) discuss the challenge of preoperative diagnosis in intraductal papillary mucinous cystic neoplasms of the pancreas and the potential use of cyst fluid mucin levels as markers of dysplasia;
(12) describe survival data and the healthrelated quality of life effects of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients diagnosed with peritoneal carcinomatosis of colonic origin; (13) discuss the potential role of ASCL1 in gastrointestinal neuroendocrine tumorigenesis; (14) explain the recurrence rate of patients with rectal cancer after combined modality therapy, and its association with adjuvant chemotherapy; and (15) review the clinical implications of positive peritoneal cytology for patients with gastric cancer.
3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall
* designated presenter
Parallel Session…Parallel Session…Parallel Session…
Breast Cancer
1:00 – 3:00 pm Friday
Room 220 • America’s Center
Moderators: Peter D. Beitsch, MD* and David J. Winchester, MD**
*Disclosure: Speaker, Honorarium: SenoRx, Hologic, Xoft, Agendia, Genomic Health **Disclosure: None
1:00 pm Consequences of Axillary Ultrasound in T2 or Greater Tumors for Patients with Invasive Breast Cancer (16)
• Lee,1* J. Eatrides,2 A. Chau,1 J.V. Kiluk,1
• Khakpour,1 W.B. Carter,1 C. Laronga,1 C.E. Cox.1
1. Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL; 2. University of South Florida College of Medicine, Tampa, FL.
Disclosure: None
1:15 pm Survival Benefit of Surgery in Stage IV Breast Cancer Patients? (17)
A. Holt,* R. Nelson, L. Kruper. City Of Hope, Duarte, CA.
Disclosure: None
1:30 pm Local Control Following Single Dose Intraoperative Radiotherapy Prior to Partial Mastectomy for Early Stage Breast Cancer (18)
D.W. Ollila,* R.J. Kimple, N. KlauberDeMore,
C.M. Kuzmiak, D. Pavic, J. Lian, C.A. Livasy,
W.M. Chiu, D.T. Moore, C.I. Sartor. University of NC at Chapel Hill, Chapel Hill, NC.
Disclosure: None
1:45 pm Morbidity of Sentinel Node Biopsy: Relationship Between Number of Excised Lymph Nodes and Lymphedema (19)
L. Wiechmann,* J.I. Goldberg, E.R. Riedel,
K.J. Van Zee. Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None
* designated presenter
2:00 pm Disseminated Tumor Cells in Histologic Subtypes Of Stage I-III Breast Cancer Patients (20)
A. Lucci,* S. Krishnamurthy, A. Lodhi, C. Hall,
B. Singh. Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Disclosure: None
2:15 pm Minimal Disease in the Sentinel Lymph Node: How to Best Measure Sentinel Node Micrometastases to Predict Risk of Additional Non-Sentinel Lymph Node Disease (21)
S. Kumar,* M. Bramlage, L.M. Jacks, J.I. Goldberg,
S.M. Patil, D.D. Giri, K.J. Van Zee. Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None
2:30 pm Ductal Carcinoma in Situ of the Breast Treated with Accelerated Partial Breast Irradiation Using Balloon Based Brachytherapy (22)
P.Z. Israel,1* F.A. Vicini,2 A.B. Robbins,1 P. Shroff,1
K.L. Haile,3 K.A. Grier,4 M. Lyden.5 1. The Breast Center, Marietta, GA; 2. William Beaumont Hospital, Department of Radiation Oncology, Royal Oak, MI;
3. WellStar Kennestone Hospital, Department of Radiation Oncology, Marietta, GA; 4. WellStar Cancer Data Center, Marietta, GA; 5. BioStat International, Inc., Tampa, FL.
Disclosure: None
2:45 pm Early Evidence of Better Cosmetic Outcome after Intraoperative Radiotherapy Compared with External Beam Radiotherapy for Early Breast Cancer: Objective Assessment of Patients from a Randomized Controlled Trial (23)
M. Keshtgar,1* N.R. Williams,1 T. Corica,2
R. Hedges,2 C. Saunders,2 D. Joseph.2 1. Royal Free and UCL Medical School, London, United Kingdom;
2. Sir Charles Gairdner Hospital, Perth, WA, Australia.
Disclosure: None
* designated presenter
Objectives: Upon completion of this session, participants should be able to: (16) discuss the role of preoperative axillary ultrasound with needle biopsy of axillary nodes in breast cancer patients with a clinical tumor size of 2 centimeters or greater;
(17) examine the impact of surgery in Stage IV breast cancer patients; (18) discuss the results of a completed phase II intraoperative radiation therapy trial for early stage breast cancer patients; (19) discuss available data on the relationship between number of sentinel nodes removed and occurrence of lymphedema and summarize the risk factors associated with the occurrence of lymphedema; (20) describe rates of micrometastatic disease in different histologic subtypes of breast cancer;
(21) identify factors associated with nonsentinel lymph node positivity in patients with micrometastasis and isolated tumor cells in the sentinel node and recognize the relationship between three methods of measurement of micrometastasis and isolated tumor cells; (22) discuss the potential application of APBI in select patients with pure DCIS; and (23) describe the role of an objective assessment tool and its use in evaluating cosmetic outcomes of two types of radiotherapy for early breast cancer.
3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall
Cast your vote for the Best Science and Clinical Posters.
Ballots must be submitted by 1:00 pm Saturday.
* designated presenter
Order Session DVDs HERE while supplies last.
Parallel Session…Parallel Session…Parallel Session…
Melanoma
1:00 – 3:00 pm Friday Room 230-231 • America’s Center
Moderators: Dennis L. Rousseau, Jr., MD, PhD* and Michael S. Sabel, MD**
*Disclosure: None **Disclosure: Speaker, Honorarium, Research Grant: Schering
1:00 pm The Analysis of Molecular and Pathologic Prognostic Factors in Melanoma Patients with Positive Sentinel Lymph Node (SLN) Biopsy after Completion Lymph Node Dissection (CLND): Multi-Marker Reverse Transcriptase-Polymerase Chain Reaction (MM-RT-PCR) Assay in Lymphatic Drainage (LY) and SLN Tumor Burden (24)
P. Rutkowski,1* Z.I. Nowecki,1 A.C. Van Akkooi,2
J. Kulik,1 W. Michej,1 J.A. Siedlecki,1 A.M. Eggermont,2 W. Ruka.1 1. Soft Tissue/Bone Sarcoma and Melanoma, Cancer CenterInstitute Warsaw, Warsaw, Poland; 2. Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Disclosure: None
1:15 pm The Prognostic Significance of Non-Sentinel Lymph Node Metastasis in Melanoma (25)
R.E. Brown,1* M.I. Ross,2 M.J. Edwards,3
R.D. Noyes,4 D.S. Reintgen,5 L. Hagendoorn,6
A.J. Stromberg,7 R.C. Martin,1 K.M. McMasters,1
C.R. Scoggins.1 1. University of Louisville, Louisville, KY; 2. University of Texas, MD Anderson Cancer Center, Houston, TX; 3. University of Cincinnati, Cincinnati, OH; 4. LDS Hospital, Salt Lake City, UT;
1 Lakeland Regional Cancer Center, Lakeland, FL;
2 Advertek, Inc, Louisville, KY; 7. University of Kentucky, Lexington, KY.
Disclosure: None
1:30 pm Tumor Dormancy in Melanoma (26)
S.T. Steen,* D. Morton, X. Ye, M. Faries. John Wayne Cancer Institute, Santa Monica, CA.
Disclosure: None
* designated presenter
1:45 pm Recurrence of Head and Neck Melanoma is not Affected by Reducing Margins of Wide Local Excision (WLE) (27)
J.D. Wayne,* J.Y. Kim, V. Rawlani, D.W. Buck II,
S.A. Johnson. Department of Surgery, Feinberg School of Medicine, Chicago, IL.
Disclosure: None
2:00 pm Targeting N-Cadherin to Augment the Efficacy of Regional Chemotherapy: A Potential Double-Edged Sword? (28)
H. Toshimitsu,* J.C. Padussis, R. Turley,
C.K. Augustine, D.S. Tyler. Surgery, Duke University, Durham, NC.
Disclosure: None
2:15 pm Growing Experience with Videoscopic Inguinal Lymphadenectomy (VIL): Moving Towards Better Outcomes (29)
K.A. Delman,* D.A. Kooby, M. Rizzo, K. Ogan,
S.K. Maithel, V. Master. Surgical Oncology, Emory University School of Medicine, Atlanta, GA.
Disclosure: None
2:30 pm Morbidity and Length of Stay with Complete Lymph Node Dissection in Melanoma: Results of MSLT1 Trial (30)
M.B. Faries,1* J.F. Thompson,3 H.J. Wang,2
D.L. Morton,1 M. MSLT Study Group.1 1. John Wayne Cancer Institute, Santa Monica, CA; 2. UCLA Biostatistics Department, Los Angeles, CA; 3. Sydney Melanoma Unit, Sydney, NSW, Australia.
Disclosure: None
2:45 pm Negative Predictive Value of a Nomogram to Predict Sentinel Node Status in Melanoma Patients (31)
S. Pasquali,1* S. Mocellin,1 L.G. Campana,1
A. Vecchiato,2 E. Bonandini,3 M.C. Montesco,3
P. Del Fiore,2 D. Nitti,1 C.R. Rossi.2 1. Department of Oncological & Surgical Sciences, University of Padova, Padova, Italy; 2. Istituto Oncologico Veneto, IRCCS, Padova, Italy; 3. Department of Pathology, University of Padova, Padova, Italy.
Disclosure: None
* designated presenter
Objectives: Upon completion of this session, participants should be able to: (24) discuss the prognostic role of sentinel node (SLN) tumor burden categories according to Rotterdam criteria after completion of node dissection and identify that the positive result of lymph fluid multimarker RTPCR assay demonstrated additional prognostic value in SLNpositive melanoma patients, showing significant correlation with shorter DFS/OS; (25) discuss the importance of nonsentinel lymph node metastasis in melanoma and identify other predictive factors for survival and recurrence in melanoma patients; (26) identify factors associated with tumor dormancy in melanoma and discuss the outcomes of patients with late recurrences of melanoma; (27) explain that wide local excision margins of head and neck melanomas located near critical anatomical structures may be reduced to 0.5 cm for lesions less than 1.0 mm thick and to 1.0 cm for lesions greater than 1.0 mm thick without affecting local or overall recurrence rates; (28) discuss better targeting chemotherapy strategies for melanoma; (29) discuss the outcomes from minimally invasive inguinal lymphadenectomy and be able to characterize its advantages in the approach to inguinal metastases; (30) discuss the impact of the timing and indication for lymph node dissection on the morbidity and length of stay associated with the procedure; and (31) discuss the concept that a predictive tool based on melanoma clinicopathological features could safely improve patients selection for sentinel node biopsy when the negative predictive value is high.
3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall
* designated presenter
Parallel Session…Parallel Session…Parallel Session…
Endocrine/Head & Neck
1:00 – 3:00 pm Friday
Room 232 • America’s Center
Moderators: Herbert C. Hoover, Jr., MD* and Mira Milas, MD**
*Disclosure: Consultant, Advisory Board, Speaker: Vaccinogen, Inc. **Disclosure: None
1:00 pm Adrenal Neoplasm Masquerading as Adrenal Hemorrhage (32)
L. Benavente Chenhalls,* M.L. Richards, A. Vella,
G.B. Thompson, C.S. Grant, D.R. Farley. Mayo Clinic Rochester, Rochester, MN.
Disclosure: None
1:15 pm Sentinel Lymph Node Biopsy for Thyroid Cancer: 10 Years of Experience at a Single Institution (33)
D.K. Cunningham,1* K.A. Yao,2 R.R. Turner,1
F. Singer,1 A. Van Herle,3 A. Giuliano.1 1. John Wayne Cancer Institute, Santa Monica, CA; 2. University of Chicago, Chicago, IL; 3. St. John's Hospital, Santa Monica, CA.
Disclosure: None
1:30 pm Prophylactic Central Neck Dissection and Local Recurrence in Papillary Thyroid Cancer: A Meta-analysis (34)
T. Zetoune,* X. Keutgen, D. Buitrago, H. Shao,
B. Zhu, M. Mazumdar, T.J. Fahey, R. Zarnegar.
Weill Cornell Medical College, New York, NY.
Disclosure: None
1:45 pm Pheochromocytoma: Increased Incidence of Asymptomatic Presentation (35)
R. Lewis,1* K. Ebede,2 D. Han,1 D.L. Cohen,1
D.L. Fraker.1 1. University of Pennsylvania Health System, Philadelphia, PA; 2. Ohio State University Medical Center, Columbus, OH.
Disclosure: None
* designated presenter
2:00 pm What is the Clinical Utility of Recurrent Laryngeal Neuromonitoring During Thyroidectomy? (36)
K.A. Stevens,1* L.R. Henry,2 L.B. Horst,3
N.P. Solomon,3 G. Coppit,3 C.D. Shriver,3
A. Stojadinovic.3 1. Naval Medical Research Center, Silver Spring, MD; 2. National Naval Medical Center, Bethesda, MD; 3. Walter Reed Army Medical Center, Washington, DC.
Disclosure: None
2:15 pm Fine Needle Aspiration Cytology for Nodular Thyroid Disease: Room for Improvement (37)
D. Han,* R. Lewis, R.R. Kelz, D.L. Fraker. Surgery, University of Pennsylvania Health System, Philadelphia, PA.
Disclosure: None
2:30 pm Surgical Management of Hepatic Neuroendocrine Tumor Metastasis (38)
S.C. Mayo,1* M.C. De Jong,1 C. Pulitano,2
B.M. Clary,3 S.K. Reddy,3 T.C. Gamblin,4
D.A. Kooby,5 C.A. Staley,5 R.D. Schulick,1
M.A. Choti,1 G. Mentha,6 J. Strub,6 R.B. Adams,7
T.W. Bauer,7 A. Ferrero,8 L. Capussotti,8
T.M. Pawlik.1 1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; 2. Ospedale San Raffaele, Milan, Italy; 3. Duke Medical Center, Durham, NC; 4. University of Pittsburgh, Pittsburgh, PA; 5. Emory University School of Medicine, Atlanta, GA; 6. Hôpitaux Universitaires de Genève, Geneva, Switzerland; 7. University of Virginia, Charlottesville, VA; 8. Ospedale Mauriziano Umberto I, Turin, Italy.
Disclosure: None
2:45 pm Vitamin D Deficiency Increases the Risk of Postoperative Hypoparathyroidism Following Thyroidectomy in Malignant Disease (39)
C.S. Landry,* E.G. Grubbs, R. Berri, J.E. Lee,
N.D. Perrier. Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Disclosure: None
* designated presenter
Objectives: Upon completion of this session, participants should be able to: (32) review the clinical and pathological impact of adrenal hemorrhage in the setting of incidental adrenal neoplasms to establish proper management strategies; (33) discuss that sentinel lymph node (SLN) biopsy for thyroid cancer is feasible, that SLN disease suggests additional nonsentinel lymph node involvement, and that it is now time to proceed with larger randomized studies to investigate the full potential of this technique in the treatment algorithm of patients with thyroid cancer;
(34) assess the effect of central neck dissection in the recurrence of papillary thyroid carcinoma; (35) discuss the presenting signs and symptoms of pheochromocytoma, and the indications for catecholamine testing in patients with an adrenal mass;
(36) discuss the clinical utility of neuromonitoring in its relation to voice outcomes during thyroid surgery; (37) discuss the utility of fine needle aspirate and predictive values of FNA diagnoses in evaluating thyroid nodules; (38) discuss the role of hepatic resection in the management of patients with hepatic neuroendocrine metastasis and the impact of hormonally functional tumors on patient survival; and (39) discuss the role of vitamin D deficiency as it relates to postoperative hypoparathyroidism after thyroid surgery.
3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall
Poster Discussion Session
3:00 – 3:30 pm Friday Exhibit Hall
This session will allow for meaningful discussion and constructive critique of recent research findings. More than 300 posters will be displayed. Authors will be present.
* designated presenter
Parallel Session…Parallel Session…Parallel Session…
Cancer Forum I
3:30 – 5:30 pm Friday
Room 240 • America’s Center
Moderators: Stephen R. Grobmyer, MD* and Thomas K. Weber, MD**
*Disclosure: None **Disclosure: None
3:30 pm The Use of Antigen Specific Listeria monocytogenes for Immunotherapy Against Hepatic Colorectal Metastases (40)
K. Olino,1* S. Wada,1 B. Edil,1 X. Pan,1 K. Meckel,1
W. Weber,1 J. Slansky,2 K. Tamada,3 D. Pardoll,1
R. Schulick,1 K. Yoshimura.1 1. Johns Hopkins Medical Institutions, Baltimore, MD; 2. University of Colorado Health Sciences Center, Denver, CO;
3. University of Maryland, Baltimore, MD.
Disclosure: None
Discussant: David Linehan, MD Disclosure: Research Grant: Novartis Oncology Discussant: Ronald DeMatteo, MD
Disclosure: Consultant, Advisory Board, Speaker, Honorarium: Novartis
3:45 pm The Dual Functionality of Monoclonal Antibodies Derived from Immunogenic Tumor Associated Antigens (41)
M. Arlen,1* P. Arlen,2 A. Bristol,2 J. Luka,2
J. Kantor,2 X. Wang,2 R. Gupta.2 1. Surgery, NSUH, Great Neck, NY; 2. Neogenix Oncology, Great Neck NY, NY.
Disclosure: Employee: Neogenix Oncology
Discussant: Steven Hochwald, MD Disclosure: None Discussant: Wilbur Bowne, MD
Disclosure: None
4:00 pm TOP2A Expression is Associated with Metastasis and Essential for the Survival of Liposarcoma Cell Lines (42)
R.M. Gobble,* L.X. Qin, C. Angeles, S. Ugras,
E.R. Brill, P. DeCarolis, R. O'Connor, S. Singer.
Surgery, Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None Discussant: Robert Cantor, MD Disclosure: None
Discussant: Raphael Pollock, MD Disclosure: None
* designated presenter
4:15 pm In Vivo Tumor Targeting by Functionalized Dendrimer Nanoscale Complexes (43)
M.A. Alcala,1* C.M. Shade,2 H. Uh,2 K. Gogick,2
R.A. Modzelewski,1 D.L. Bartlett,1 Y.J. Lee,1
S. Petoud,2 C.K. Brown.1 1. Surgery, University of Pittsburgh, Pittsburgh, PA; 2. Department of Chemistry, University of Pittsburgh, Pittsburgh, PA.
Disclosure: None
Discussant: Ramsay Camp, MD Disclosure: None Discussant: Robert Martin, MD
Disclosure: Consultant: Biocompatibles, Covidien; Research Grant: Boston Scientific
4:30 pm Identification of the Target Gene Enhanced by Wnt/TCF Binding to the Common Predisposition SNP Rs6983267 at Chromosome 8q24 in Colorectal Cancer Cases (44)
K. Mimori,1* K. Yamamoto,1 T. Sato,1 K. Yamada,7
M. Watanabe,5 M. Kusunoki,9 Y. Moriya,6 S. Kudo,4
H. Mochizuki,8 K. Sugihara,3 M. Mori.2 1. Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan; 2. Graduate School of Medicine, Osaka University., Suita, Japan; 3. Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan; 4. Northern Yokohama Hospital Showa University, Yokohama, Japan; 5. Kitasato University School of Medicine, Sagami, Japan; 6. National Cancer Center, Tokyo, Japan; 7. Takano Hospital, Kumamoto, Japan; 8. National Defense Medical College, Tokorozawa, Japan; 9. Mie University, Tsu, Japan.
Disclosure: Grant/Research Support: Core Research for
Evolutional Science and Technology, JST Discussant: David Shibata, MD Disclosure: None
* designated presenter …continued on next page
Parallel Session…Parallel Session…Parallel Session…
4:45 pm A Monoclonal Antibody to Secreted Frizzled Related Protein 2 Inhibits Angiosarcoma Differentiation and Migration (45)
N. KlauberDeMore,* E. Hilliard, S. SiamakpourReihani, B. Bone, E. Rossi, D. Ketelsen,
C. Patterson. University of North Carolina at Chapel Hill, Chapel Hill, NC.
Disclosure: Employee: Chief Scientific Officer and CoFounder, Enci Therapeutics, Inc., Grant/Research Support: NIH Breast Cancer Spore Grant, NC TRACS grant, Other: Patent 'Discovery of Novel Targets for Angiogenesis Inhibition'
Discussant: Sam Yoon, MD
Disclosure: None Discussant: Martin McCarter, MD Disclosure: Consultant: Covidien; Speaker: Institute for Medical Education and Research
5:00 pm Anti-tumor Immune Responses in Human Sarcoma (46)
V.P. Balachandran,* L.M. Ocuin, M.J. Cavnar,
H. Obaid, R.P. DeMatteo. Surgery, Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None
Discussant: John Stewart, MD Disclosure: None Discussant: Richard Schulick, MD
Disclosure: None
Objectives: Upon completion of this session, participants should be able to: (40) describe basic principals of immunotherapy and the application of a genetically engineered bacterium to serve as a vaccine vector; (41) discuss the functional activity of a new class of IgG1 monoclonal antibodies that induce apoptosis of the targeted tumor with essentially no side effect produced on normal tissue in contrast to epidermal growth factor monoclonals that do not produce tumor death and produce side effects from receptors on normal tissue; (42) summarize the importance of topoisomerase II alpha gene expression for distant recurrence free survival in primary liposarcoma and survival of liposarcoma cell lines; (43) demonstrate a novel way of targeting hepatic colorectal metastases in a rat model using functionalized nanotechnological chromophoric dendrimers; (44) identify the new target gene being associated with famous SNP at 8q24 in CRC cases and physicians can focus not only on prediction of highrisk patients, but prevention of oncogenic process of CRC; (45) discuss the activity of a monoclonal antibody to SFRP2 on angiosarcoma differentiation and migration in vitro; and (46) discuss the nature of antitumor immune responses in human sarcomas.
* designated presenter
Coding and Reimbursement Committee Presents
A Practical Approach to Capturing Your Practice Dollars: From A to D/C
3:30 – 5:30 pm Friday
Room 220 • America’s Center
Moderators: Francis R. Spitz, MD* and Alan M. Yahanda, MD**
*Disclosure: None **Disclosure: None
3:35 pm Coding Fundamentals for Breast Disease
Terry Sarantou, MD
Associate Professor of Surgery Blumenthal Cancer Center Carolinas Medical Center Charlotte, NC
Disclosure: None
4:00 pm Office, OR, and Hospital Billing for Thyroid and Parathyroid Disease Rosa E. Cuenca, MD Titus Regional Medical Center Breast Wellness Center Mt. Pleasant, TX
Disclosure: None
4:25 pm Coding for Pancreatic Procedures
Jason B. Fleming, MD
Associate Professor University of Texas MD Anderson Cancer Center Houston, TX
Disclosure: None
4:50 pm Case Reviews
Objectives: At the conclusion of this session, participants should be able to: a) describe the process and strategies for coding Pancreatic, endocrine and breast procedures; b) review the process and opportunities for practice based billing; and c) identify proper documentation and billing for inpatient care.
* designated presenter
Controversies in the Management of Pancreatic Carcinoma
3:30 – 5:30 pm Friday
Room 221-228 • America’s Center
Partially supported by an educational grant from Eli Lilly & Company
Moderator: Herbert C. Hoover, Jr., MD
Disclosure: Consultant, Advisory Board, Speaker: Vaccinogen, Inc.
3:35 pm Upfront Surgical Resection or Preoperative Therapy: Who for What?
Robert A. Wolff, MD
Professor of Medicine Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston, TX
Disclosure: Research Grant: Eli Lilly and Company
3:55 pm Laparoscopic Approaches to Pancreatic Cancer: Maintaining Oncologic Standards
Michael L. Kendrick, MD
Assistant Professor of Surgery Division of Gastroenterologic and General Surgery Mayo Clinic College of Medicine Rochester, MN
Disclosure: None
4:15 pm The Critical Oncologic Steps in Pancreaticoduodenectomy: SMA Margin, Venous Resection
Douglas B. Evans, MD
Professor and Chairman of Surgery Department of Surgery Medical College of Wisconsin Milwaukee, WI
Disclosure: None
4:35 pm Who Benefits from RT of Resectable
Pancreatic Cancer? A Data-driven Guide to Patient Selection
Christopher G. Willett, MD
Leonard R. Prosnitz Professor and Chair of Radiation Oncology Department of Radiation Oncology Duke University Medical Center Durham, NC
Disclosure: None
4:55 pm Debate/Questions
Objectives: At the conclusion of this session, participants should be able to: a) explain the significance of pancreatic carcinoma in our population; b) discuss the role and indications for chemotherapy and other systemic therapies in the neoadjuvant, adjuvant and palliative clinical scenarios; c) review the data concerning radiation therapy in all stages of pancreatic carcinoma and develop an understanding of newer technologies such as intraoperative radiation therapy and cyberknife; and d) describe the indications for surgical intervention in all stages of pancreatic carcinoma and the use of open vs. minimally invasive approaches.
Claim Your CME Credit Online!
Go to the CME kiosks on Level 2 of the America’s Center to submit your session evaluations and claim your CME credit electronically.
Or login at your home or office at http://CME.surgonc.org
New This Year: Dinner Symposium
The Role of the Surgical Physician Extender in Patient Navigation
6:00 – 8:00 pm Friday
Renaissance Hotel • Majestic Ballroom Salon D
Partially supported by educational grants from the Academy of Oncology Nurse Navigators and Pfizer Inkind support provided by Journal of Multidisciplinary Cancer Care and The Oncology Nurse
Special dinner program for surgical oncology nurse practitioners and physician assistants. Seating is limited.
Moderators: Lillie Shockney, RN, BS, MAS* and Mehra Golshan, MD**
*Disclosure: Honorarium: Jones & Bartlett Publishing – royalties **Disclosure: None
6:00 pm Lillie Shockney, RN, BS, MAS
Administrative Director Johns Hopkins Avon Foundation Breast Center Associate Professor, Departments of Surgery Gynecology and Obstetrics, Baltimore, MD
Disclosure: Honorarium: Jones & Bartlett Publishing – royalties
6:30 pm Nicole Messier, RN, BSN
Clinical Program Coordinator Fletcher Allen Health Care Burlington, VT, Disclosure: None
7:00 pm Panel Discussion/Questions
Objectives: At the conclusion of this session, participants should be able to: a) discuss the history of patient navigation as it relates to cancer care; b) recognize the types of barriers associated with the delivery of efficient, quality cancer care; c) identify at least two ways a surgical physician extender can directly and positively impact a patient’s coordination of care across a community or academic cancer center; d) describe the process of assessing a patient’s medical, financial, and psychological needs that may impact timely care as well as adherence to the patient’s recommended cancer treatment; and e) differentiate between the role of the nurse navigator and the surgical oncology physician extender as well as the opportunities to share navigation responsibilities to enhance the cancer diagnosis and treatment experience.
Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters
Order Session DVDs HERE while supplies last.